Article

Cleveland Clinic's Cole Eye Institute receives $310,000 grant

Cleveland, OH-The Cleveland Clinic's Cole Eye Institute and biotechnology firm Arteriocyte Inc. have been awarded a $310,000 grant to study the treatment of eye disease.

Cleveland, OH-The Cleveland Clinic's Cole Eye Institute and biotechnology firm Arteriocyte Inc. have been awarded a $310,000 grant to study the treatment of eye disease.

One of the main focuses of the research is to treat diabetic retinopathy.

According to the American Academy of Ophthalmology, the disease is the leading cause of blindness among working Americans.

The study will evaluate whether a cellular therapy product by Arteriocyte could prevent the initial vaso-degenerative phase of the disease.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
© 2025 MJH Life Sciences

All rights reserved.